Table 2 Linear regression predicting yearly eGFR change
Crude coefficient (95% CI) | Crude p | Adjusted coefficient (95% CI) | Adjusted p | |
|---|---|---|---|---|
Age | − 0.26 (− 1.94, 1.42) | 0.764 | − 2.39 (− 4.84, 0.05) | 0.056 |
Sex (men vs. women) | − 13.37 (− 66.81, 40.07) | 0.624 | − 20.04 (− 75.92, 35.84) | 0.482 |
Baseline hypertension | − 11.69 (− 107.43, 84.05) | 0.811 | − 7.87 (− 112.71, 96.96) | 0.883 |
Baseline diabetes | − 0.47 (− 145.63, 144.69) | 0.995 | 25.83 (− 128.75, 180.41) | 0.743 |
Primary psychiatric diagnoses, ICD-10 (ref. = F20–29) | ||||
F30–31 | − 16.45 (− 85.42, 52.53) | 0.640 | − 14.45 (− 86.41, 57.52) | 0.694 |
F32–33 | 53.15 (− 27.04, 133.35) | 0.194 | 62.95 (− 20.88, 146.78) | 0.142 |
Drug (lithium vs. valproate) | − 7.5 (− 64.9, 49.9) | 0.798 | − 3.57 (− 81.89, 74.76) | 0.929 |
Baseline eGFR | − 1.03 (− 2.49, 0.43) | 0.168 | − 2.17 (− 4.15, − 0.20) | 0.031 |
Average daily dose | − 0.03 (− 0.17, 0.1) | 0.629 | 0.02 (− 0.15, 0.18) | 0.857 |
Years on treatment | 0.01 (− 5.34, 5.36) | 0.997 | − 1.47 (− 7.07, 4.14) | 0.608 |
Episodes of lithium toxicity (≥ 1 episode) | ||||
TDM > 0.8 mmol/L | − 5.27 (− 78.89, 68.36) | 0.888 | 2.78 (− 114.5, 120.06) | 0.963 |
TDM > 1.0 mmol/L | − 7.50 (− 182.52, 167.53) | 0.933 | − 9.05 (− 220.15, 202.06) | 0.933 |
TDM > 1.2 mmol/L | − 7.77 (− 108.68, 93.14) | 0.880 | 1.54 (− 150.36, 153.43) | 0.984 |